Latest News
Cerenome, Inc.
- Cerenome announces new dual mechanism of action for REYOBIQ
- Cerenome presents preclinical data on REYOBIQ cancer mechanism
- Cerenome shares preclinical data on REYOBIQ immune effects
- Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
- Cerenome Secures in-Network Agreement With Fl
- Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
- Cerenome inks deal with Florida Blue to expand CNSide CSF tumor and molecular testing coverage
- Cerenome Launches Two CSF Molecular Profiling Tests for CNS Cancers
- Cerenome Subsidiary CNSide Diagnostics Launches CSF Molecular Profiling Tests for CNS Cancers
- Cerenome Updates Investor Presentation on CNS Oncology Strategy
- Cerenome Reports CNSide Q3 2026 Progress on Coverage Expansion, Medicare Pricing and Testing Menu Growth
- Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Headlines from the last 30 days, linking to the original publishers. See all market news →